<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592823</url>
  </required_header>
  <id_info>
    <org_study_id>AF-1</org_study_id>
    <nct_id>NCT03592823</nct_id>
  </id_info>
  <brief_title>Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence</brief_title>
  <official_title>Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation is the most common arrhythmia in clinic. It can lead to heart failure or&#xD;
      stroke, and has a high disability rate and mortality rate. At present, although&#xD;
      radiofrequency ablation can cure atrial fibrillation, the success rate is only 50~70%, and&#xD;
      has a high recurrence rate. In recent decades, no effective new antiarrhythmic drugs have&#xD;
      been introduced, but there are side effects in long-term application of the existing&#xD;
      antiarrhythmic drugs. Therefore, it is urgent to provide new and effective antiarrhythmic&#xD;
      drugs.&#xD;
&#xD;
      Autophagy level of atrial myocytes in atrial fibrillation patients was significantly higher&#xD;
      than that in sinus rhythm. Hydrochloroquine (HCQ) is a hydroxychloroquine sulfate composed of&#xD;
      4- amino quinoline compounds. As an effective inhibitor for autophagy, HCQ could effectively&#xD;
      prevent the increased autophagy level of atrial myocytes in atrial fibrillation rabbits,&#xD;
      prevent atrial effective refractory period (AERP) shortening, and decrease the rate and&#xD;
      duration of atrial fibrillation.&#xD;
&#xD;
      At present, hydroxychloroquine is mainly used in the treatment of rheumatic immune system&#xD;
      diseases and anti malaria. Because of its good safety and small side effects, HCQ has become&#xD;
      an indispensable member of drugs in the combined treatment of rheumatoid arthritis and&#xD;
      systemic lupus erythematosus patients. In recent years, studies have reported that&#xD;
      hydroxychloroquine plays an important role in the prevention and treatment of cardiovascular&#xD;
      diseases. Chloroquine could effectively shorten the action potential of atrial myocytes by&#xD;
      blocking the inward rectifier potassium ion channel (Kir2.1) and reducing the inward&#xD;
      potassium ion current Ik1. HCQ could also reduce 72% (P=0.002), and 70% for the risk of&#xD;
      coronary heart disease, stroke, and transient ischemic disease. So the investigators&#xD;
      speculate that HCQ may be a potential drug to block the occurrence of acute atrial&#xD;
      fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence rate of atrial fibrillation after radiofrequency catheter ablation</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Recurrence rate of atrial fibrillation after radiofrequency catheter ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Side effects including Eye diseases, skin damage, death, heart failure, malignant arrhythmia and stroke.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>receiving radiofrequency ablation and anticoagulant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydrochloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving radiofrequency ablation, anticoagulant therapy and hydrochloroquine treatment (200 mg,bidpo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate 200 Mg Tablet</intervention_name>
    <description>200 mg, bidpo.</description>
    <arm_group_label>hydrochloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Successful radiofrequency ablation of atrial fibrillation within 24 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cerebrovascular disease: ischemic stroke, cerebral haemorrhage and&#xD;
             transient ischemic attack.&#xD;
&#xD;
          -  History of cardiovascular disease:unstable angina, myocardial infarction, coronary&#xD;
             revascularization and congestive heart failure.&#xD;
&#xD;
          -  History of renal impairment.&#xD;
&#xD;
          -  History of Type I diabetes mellitus or Type II diabetes uncontrolled.&#xD;
&#xD;
          -  History of liver impairment.&#xD;
&#xD;
          -  History of alcoholism or drug abuse.&#xD;
&#xD;
          -  Known severe skin rash or damage.&#xD;
&#xD;
          -  Known retinal pigmentation and visual field defect.&#xD;
&#xD;
          -  Allergy to any component of hydroxychloroquine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yue Li, MD</last_name>
    <phone>86-451-85555673</phone>
    <email>ly99ly@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Electrocardiograph</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Shi, MD</last_name>
      <phone>86-451-85555672</phone>
      <email>yidashijing@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

